GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.27 Billion KRW | 13.87% |
| 2022 | 5.5 Billion KRW | -22.45% |
| 2021 | 7.1 Billion KRW | 794.46% |
| 2020 | 794.08 Million KRW | -60.54% |
| 2019 | 2.01 Billion KRW | 0.0% |
| 2018 | - KRW | -100.0% |
| 2017 | 214.46 Million KRW | 0.0% |
| 2016 | - KRW | -100.0% |
| 2015 | 727.71 Million KRW | -33.23% |
| 2014 | 1.08 Billion KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | -100.0% |
| 2011 | 825.74 Million KRW | 0.0% |
| 2010 | - KRW | -100.0% |
| 2009 | 7.87 Billion KRW | 0.0% |
| 2008 | - KRW | 0.0% |
| 2007 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 8.32 Billion KRW | 32.75% |
| 2024 Q2 | 11.3 Billion KRW | 35.79% |
| 2023 Q1 | 5.56 Billion KRW | 1.1% |
| 2023 Q2 | 4.56 Billion KRW | -17.99% |
| 2023 FY | 6.27 Billion KRW | 13.87% |
| 2023 Q3 | 4.37 Billion KRW | -4.15% |
| 2023 Q4 | 6.27 Billion KRW | 43.3% |
| 2022 Q1 | 7.17 Billion KRW | 1.0% |
| 2022 Q3 | 7.79 Billion KRW | 5.4% |
| 2022 Q4 | 5.5 Billion KRW | -29.31% |
| 2022 FY | 5.5 Billion KRW | -22.45% |
| 2022 Q2 | 7.39 Billion KRW | 3.06% |
| 2021 FY | 7.1 Billion KRW | 794.46% |
| 2021 Q1 | 820.94 Million KRW | 3.38% |
| 2021 Q2 | 3.59 Billion KRW | 337.75% |
| 2021 Q3 | 7.81 Billion KRW | 117.52% |
| 2021 Q4 | 7.1 Billion KRW | -9.14% |
| 2020 FY | 794.08 Million KRW | -60.54% |
| 2020 Q2 | 2.22 Billion KRW | 12.07% |
| 2020 Q3 | 2.18 Billion KRW | -1.83% |
| 2020 Q4 | 794.08 Million KRW | -63.64% |
| 2020 Q1 | 1.98 Billion KRW | -1.36% |
| 2019 Q1 | 3.16 Billion KRW | 0.0% |
| 2019 FY | 2.01 Billion KRW | 0.0% |
| 2019 Q3 | 3.07 Billion KRW | 3.3% |
| 2019 Q2 | 2.97 Billion KRW | -6.01% |
| 2019 Q4 | 2.01 Billion KRW | -34.49% |
| 2018 Q3 | 10.6 Billion KRW | 3.8% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 Q2 | 10.21 Billion KRW | 0.0% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 FY | - KRW | -100.0% |
| 2017 FY | 214.46 Million KRW | 0.0% |
| 2017 Q4 | 214.46 Million KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2016 Q2 | 19.91 Billion KRW | 2341.52% |
| 2016 FY | - KRW | -100.0% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 Q3 | 20.26 Billion KRW | 1.77% |
| 2016 Q1 | 815.72 Million KRW | 12.09% |
| 2015 FY | 727.71 Million KRW | -33.23% |
| 2015 Q4 | 727.71 Million KRW | 0.0% |
| 2015 Q3 | - KRW | -100.0% |
| 2015 Q2 | 1.3 Billion KRW | 9.39% |
| 2015 Q1 | 1.19 Billion KRW | 9.78% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 FY | 1.08 Billion KRW | 0.0% |
| 2014 Q4 | 1.08 Billion KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | - KRW | -100.0% |
| 2012 Q1 | 6.8 Billion KRW | 0.0% |
| 2011 FY | 825.74 Million KRW | 0.0% |
| 2011 Q3 | - KRW | 0.0% |
| 2011 Q2 | - KRW | 0.0% |
| 2011 Q1 | - KRW | 0.0% |
| 2010 Q1 | 8.03 Billion KRW | 0.0% |
| 2010 FY | - KRW | -100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q2 | 8.21 Billion KRW | 2.21% |
| 2009 FY | 7.87 Billion KRW | 0.0% |
| 2009 Q3 | 7.7 Billion KRW | 0.0% |
| 2009 Q2 | - KRW | 0.0% |
| 2009 Q1 | - KRW | 0.0% |
| 2008 Q1 | - KRW | 0.0% |
| 2008 Q2 | - KRW | 0.0% |
| 2008 Q3 | - KRW | 0.0% |
| 2008 Q4 | - KRW | 0.0% |
| 2008 FY | - KRW | 0.0% |
| 2007 Q2 | - KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | - KRW | 0.0% |
| 2007 Q3 | - KRW | 0.0% |
| 2007 Q1 | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 2.43 Billion KRW | -157.444% |
| Green Cross Holdings Corporation | 216.35 Billion KRW | 97.101% |
| Green Cross Holdings Corporation | 84.89 Billion KRW | 92.611% |
| Pharmicell Co., Ltd. | 390.21 Million KRW | -1507.505% |
| Green Cross Corporation | 84.89 Billion KRW | 92.611% |
| Celltrion, Inc. | 99.13 Billion KRW | 93.672% |
| Samsung Biologics Co.,Ltd. | 377.39 Billion KRW | 98.338% |
| SK bioscience Co.,Ltd. | 12.43 Billion KRW | 49.56% |
| SK Biopharmaceuticals Co., Ltd. | 94.48 Billion KRW | 93.361% |
| Prestige BioPharma Limited | 40.87 Billion KRW | 84.652% |